HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increases antibiotic susceptibility of multidrug resistant staphylococci
Auf einen Blick
- Projektleiter/in : Prof. Dr. Rainer Riedl
- Projektteam : Dr. Mathieu Chellat, Luka Raguz
- Projektvolumen : CHF 1'979'276
- Projektstatus : abgeschlossen
- Drittmittelgeber : KTI (KTI-Projekt / Projekt Nr. 15235.1 PFLS-LS)
- Projektpartner : BioVersys AG
- Kontaktperson : Rainer Riedl
Beschreibung
A new and highly innovative treatment will be realized by a novel and patentable small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic staphylococci. The consortium integrates a screening platform, biophysical characterization of small molecules, medicinal chemistry, high-end characterization of mode of action and the in vivo mouse models, to develop initial HIT compounds into preclinical candidates.